ALSO NOTED: FDA rejects Risperdal for Alzheimer's; Elan CEO bullish on Tysabri's return; Myogen, Novartis expand pact; and much

> Johnson & Johnson says the FDA has turned thumb's down on Risperdal as a treatment of psychosis in Alzheimer's. Release

> Elan CEO Kelly Martin told reporters that the return of the company's MS drug Tysabri is a question of when "and not a question of if." Article

> Myogen and Novartis are expanding their drug pact to include another heart disease therapy. Story

> Metric: Within months of receiving prescriptions for drugs to lower high blood pressure and reduce cholesterol, large numbers of patients stop taking the pharmaceuticals as prescribed. Article

> The FDA has approved AstraZeneca's Merrem for skin infections. Release

> GlaxoSmithKline Pharmaceuticals and Japan's Eisai have struck a deal to market Eisai's ulcer drug in India. Story

> India's Alchemist has bought Delhi-based Valiant Healthcare for 45 million rupees. Alchemist is also planning to build a drug-making plant in Uttaranchal. Story

> Toronto's Generex Biotechnology has been allowed additional time to meet Nasdaq's listing requirements. Release

And Finally... Sen. Arlen Specter (R-Penn.) says he has enough votes in the Senate to override a presidential veto on stem cell legislation. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.